December 28, 2005 -- Celgene received FDA approval of Revlimid, its second-generation version of Thalidomide, as a treatment for patients with myelodysplastic syndrome; AstraZeneca signed another deal with a smaller biotech, paying $300 million to collaborate with Targacept on an Alzheimer’s drug; Pfizer entered a four-year collaboration with Perlegen to predict patient responses to particular medicines (yesterday, Pfizer bought a stake in the company); Affymetrix moved higher on news it would be added to the S&P Mid-Cap 400; andDiscovery Labs will pay $16 million for the Totowa, NJ operations of Laureate Pharma , which supplies Discovery with Surfaxin. The Centient Biotech 2000™ rose 3 points to 3977.52, an increase of .08%. More details...
